TAMI MILLER: Open Payments
NPI 1174164263 · BOISE, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$472 in 23 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $380 · 2025 $472
Food & beverage: $472
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 5 | $102 |
| AstraZeneca Pharmaceuticals LP | 3 | $56 |
| Lilly USA, LLC | 3 | $52 |
| PFIZER INC. | 2 | $45 |
| Novo Nordisk Inc | 2 | $39 |
| GlaxoSmithKline, LLC. | 2 | $39 |
| Novartis Pharmaceuticals Corporation | 1 | $31 |
| Dexcom, Inc. | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Verona Pharma, Inc. | 1 | $23 |
Products named: MOUNJARO, UBRELVY, FARXIGA, TRELEGY ELLIPTA, VRAYLAR, LEQVIO, Dexcom G6 Transmitter, RECORLEV.
Industry payments across ID — which companies pay providers there.
